Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Mol Cancer ; 13: 113, 2014 May 20.
Article in English | MEDLINE | ID: mdl-24884804

ABSTRACT

BACKGROUND: Tumor heterogeneity and the plasticity of cancer cells present challenges for effective clinical diagnosis and therapy. Such challenges are epitomized by neuroendocrine transdifferentiation (NED) and the emergence of neuroendocrine-like cancer cells in prostate tumors. This phenomenon frequently arises from androgen-depleted prostate adenocarcinoma and is associated with the development of castration-resistant prostate cancer and poor prognosis. RESULTS: In this study, we showed that NED was evoked in both androgen receptor (AR)-positive and AR-negative prostate epithelial cell lines by growing the cells to a high density. Androgen depletion and high-density cultivation were both associated with cell cycle arrest and deregulated expression of several cell cycle regulators, such as p27Kip1, members of the cyclin D protein family, and Cdk2. Dual inhibition of Cdk1 and Cdk2 using pharmacological inhibitor or RNAi led to modulation of the cell cycle and promotion of NED. We further demonstrated that the cyclic adenosine 3', 5'-monophosphate (cAMP)-mediated pathway is activated in the high-density conditions. Importantly, inhibition of cAMP signaling using a specific inhibitor of adenylate cyclase, MDL-12330A, abolished the promotion of NED by high cell density. CONCLUSIONS: Taken together, our results imply a new relationship between cell cycle attenuation and promotion of NED and suggest high cell density as a trigger for cAMP signaling that can mediate reversible NED in prostate cancer cells.


Subject(s)
Cell Transdifferentiation , Neuroendocrine Cells/pathology , Prostatic Neoplasms/pathology , Androgens/pharmacology , CDC2 Protein Kinase , Cell Count , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Transdifferentiation/drug effects , Cyclic AMP/metabolism , Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinases/metabolism , Epithelial Cells/drug effects , Epithelial Cells/enzymology , Epithelial Cells/pathology , Humans , Immunohistochemistry , Male , Neuroendocrine Cells/drug effects , Protein Kinase Inhibitors/pharmacology , Receptors, Androgen/metabolism , Signal Transduction/drug effects
2.
Cytometry A ; 83(5): 472-82, 2013 May.
Article in English | MEDLINE | ID: mdl-23450810

ABSTRACT

The clonogenic assay is a well-established in vitro method for testing the survival and proliferative capability of cells. It can be used to determine the cytotoxic effects of various treatments including chemotherapeutics and ionizing radiation. However, this approach can also characterize cells with different phenotypes and biological properties, such as stem cells or cancer stem cells. In this study, we implemented a faster and more precise method for assessing the cloning efficiency of cancer stem-like cells that were characterized and separated using a high-speed cell sorter. Cell plating onto a microplate using an automatic cell deposition unit was performed in a single-cell or dilution rank mode by the fluorescence-activated cell sorting method. We tested the new automatic cell-cloning assay (ACCA) on selected cancer cell lines and compared it with the manual approach. The obtained results were also compared with the results of the limiting dilution assay for different cell lines. We applied the ACCA to analyze the cloning capacity of different subpopulations of prostate and colon cancer cells based on the expression of the characteristic markers of stem (CD44 and CD133) and cancer stem cells (TROP-2, CD49f, and CD44). Our results revealed that the novel ACCA is a straightforward approach for determining the clonogenic capacity of cancer stem-like cells identified in both cell lines and patient samples.


Subject(s)
Cell Proliferation , Colonic Neoplasms/pathology , Flow Cytometry/methods , Neoplastic Stem Cells/pathology , Prostatic Neoplasms/pathology , Tumor Stem Cell Assay/methods , AC133 Antigen , Antigens, CD/metabolism , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Cell Adhesion Molecules/metabolism , Cell Line, Tumor , Cell Survival , Colonic Neoplasms/metabolism , Glycoproteins/metabolism , Humans , Hyaluronan Receptors/metabolism , In Vitro Techniques , Integrin alpha6/metabolism , Male , Neoplastic Stem Cells/metabolism , Peptides/metabolism , Prostatic Neoplasms/metabolism
3.
Mol Cancer ; 11: 15, 2012 Mar 23.
Article in English | MEDLINE | ID: mdl-22439866

ABSTRACT

BACKGROUND: The c-Myb transcription factor is essential for the maintenance of stem-progenitor cells in bone marrow, colon epithelia, and neurogenic niches. c-Myb malfunction contributes to several types of malignancies including breast cancer. However, the function of c-Myb in the metastatic spread of breast tumors remains unexplored. In this study, we report a novel role of c-Myb in the control of specific proteases that regulate the matrix-dependent invasion of breast cancer cells. RESULTS: Ectopically expressed c-Myb enhanced migration and ability of human MDA-MB-231 and mouse 4T1 mammary cancer cells to invade Matrigel but not the collagen I matrix in vitro. c-Myb strongly increased the expression/activity of cathepsin D and matrix metalloproteinase (MMP) 9 and significantly downregulated MMP1. The gene coding for cathepsin D was suggested as the c-Myb-responsive gene and downstream effector of the migration-promoting function of c-Myb. Finally, we demonstrated that c-Myb delayed the growth of mammary tumors in BALB/c mice and affected the metastatic potential of breast cancer cells in an organ-specific manner. CONCLUSIONS: This study identified c-Myb as a matrix-dependent regulator of invasive behavior of breast cancer cells.


Subject(s)
Breast Neoplasms/metabolism , Cathepsin D/metabolism , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 9/metabolism , Proto-Oncogene Proteins c-myb/metabolism , Animals , Breast Neoplasms/genetics , Cathepsin D/genetics , Cell Line, Tumor , Cell Movement/genetics , Cell Movement/physiology , Electrophoresis, Polyacrylamide Gel , Female , Humans , Immunoblotting , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 9/genetics , Mice , Mice, Inbred BALB C , Neoplasm Metastasis/genetics , Neoplasm Metastasis/physiopathology , Proto-Oncogene Proteins c-myb/genetics , RNA, Small Interfering , Real-Time Polymerase Chain Reaction
4.
Prostate ; 71(12): 1332-43, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21321977

ABSTRACT

BACKGROUND: Epithelial-mesenchymal transition (EMT) underlying cancer cell invasion and metastasis has been thoroughly studied in prostate cancer. Although EMT markers have been clinically observed in benign prostate hyperplasia, molecular events underlying the onset and progression of EMT in benign prostate cells have not been described. METHODS: EMT in BPH-1 cells was induced by TGF-ß1 treatment and the kinetics of expression of EMT markers, regulators, and selected miRNAs was assessed by western blotting and quantitative RT-PCR. RESULTS: EMT in BPH-1 cells was accompanied by rapid up-regulation of SNAI2/Slug and ZEB1 transcription factors, while changes in expression levels of ZEB2 and miR-200 family members were observed after extended time intervals. Invasive phenotype with EMT hallmarks, characterizing tumorigenic clones derived from BPH-1 cells, was associated with increased mRNA levels of SNAI2, ZEB1, and ZEB2, but was not associated with significant changes in basal levels of miR-200 family members. RNA interference revealed that SNAI2/Slug is crucial for TGF-ß1-induced vimentin up-regulation and migration of BPH-1 cells. CONCLUSIONS: This study suggests that in BPH-1 cells the transcription factor SNAI2/Slug is important for EMT initiation, while the ZEB family of transcription factors in cooperation with the miR-200 family may oppose the reversal of the EMT phenotype.


Subject(s)
Epithelial-Mesenchymal Transition , Prostatic Hyperplasia/physiopathology , Transcription Factors/biosynthesis , Transforming Growth Factor beta1/pharmacology , Biomarkers/metabolism , Cell Line , Cell Movement , Epithelial-Mesenchymal Transition/genetics , Homeodomain Proteins/genetics , Humans , Kinetics , Male , MicroRNAs/metabolism , Neoplasm Invasiveness/genetics , Phenotype , RNA, Messenger/metabolism , Repressor Proteins/genetics , Snail Family Transcription Factors , Transcription Factors/genetics , Up-Regulation/drug effects , Vimentin/metabolism , Zinc Finger E-box Binding Homeobox 2 , Zinc Finger E-box-Binding Homeobox 1
5.
Biol Proced Online ; 11: 316-24, 2009 Sep 12.
Article in English | MEDLINE | ID: mdl-19756912

ABSTRACT

The plasticity of differentiated adult cells could have a great therapeutic potential, but at the same time, it is characteristic of progression of serious pathological states such as cancer and fibrosis. In this study, we report on the application of a real-time noninvasive system for dynamic monitoring of cellular plasticity. Analysis of the cell impedance profile recorded as cell index using a real-time cell analyzer revealed its significant increase after the treatment of prostate epithelial cells with the transforming growth factor-ß1. Changes in the cell index profile were paralleled with cytoskeleton rebuilding and induction of epithelial-mesenchymal transition and negatively correlated with cell proliferation. This novel application of such approach demonstrated a great potential of the impedance-based system for noninvasive and real-time monitoring of cellular fate.

6.
Oncotarget ; 6(34): 36156-71, 2015 Nov 03.
Article in English | MEDLINE | ID: mdl-26416355

ABSTRACT

Plasticity of cancer cells, manifested by transitions between epithelial and mesenchymal phenotypes, represents a challenging issue in the treatment of neoplasias. Both epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are implicated in the processes of metastasis formation and acquisition of stem cell-like properties. Mouse double minute (MDM) 2 and MDMX are important players in cancer progression, as they act as regulators of p53, but their function in EMT and metastasis may be contradictory. Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression. Modulation of EMT-accompanying changes in MDM2 expression in benign and transformed prostate epithelial cells influences their migration capacity and sensitivity to docetaxel. Analysis of putative mechanisms of MDM2 expression control demonstrates that in the context of defective p53 function, MDM2 expression is regulated by EMT-inducing transcription factors Slug and Twist. These results provide an alternative context-specific role of MDM2 in EMT, cell migration, metastasis, and therapy resistance.


Subject(s)
Breast Neoplasms/metabolism , Epithelial-Mesenchymal Transition/physiology , Nuclear Proteins/biosynthesis , Prostatic Neoplasms/metabolism , Proto-Oncogene Proteins c-mdm2/biosynthesis , Proto-Oncogene Proteins/biosynthesis , Animals , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Cycle Proteins , Cell Line, Tumor , Female , Heterografts , Humans , Male , Mice , Mice, Nude , Phenotype , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Transfection
7.
Cell Signal ; 24(8): 1665-76, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22560882

ABSTRACT

Crosstalk between the aryl hydrocarbon receptor (AhR) and transforming growth factor-ß1 (TGF-ß1) signaling has been observed in various experimental models. However, both molecular mechanism underlying this crosstalk and tissue-specific context of this interaction are still only partially understood. In a model of human non-tumorigenic prostate epithelial cells BPH-1, derived from the benign prostatic hyperplasia, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) persistently activates the AhR signaling pathway and induces expression of xenobiotic metabolizing enzymes, such as CYP1A1 or CYP1B1. Here we demonstrate that TGF-ß1 suppresses the AhR-mediated gene expression through multiple mechanisms, involving inhibition of AhR expression and down-regulation of nuclear AhR, via a SMAD4-dependent pathway. In contrast, TCDD-induced AhR signaling does not affect either TGF-ß1-regulated gene expression or epithelial-to-mesenchymal transition. These observations suggest that, in the context of prostate epithelium, TGF-ß1 signaling plays a dominant role in the crosstalk with AhR signaling pathway. Given the importance of TGF-ß1 signaling in regulation of prostate epithelial tissue homeostasis, as well as the recently revealed role of AhR in prostate development and tumorigenesis, the above findings contribute to our understanding of the mechanisms underlying the crosstalk between the two signaling pathways in the prostate-specific context.


Subject(s)
Epithelial Cells/drug effects , Epithelial Cells/metabolism , Polychlorinated Dibenzodioxins/pharmacology , Prostate/cytology , Signal Transduction/drug effects , Transforming Growth Factor beta1/metabolism , Cells, Cultured , Humans , Ligands , Male , Receptors, Aryl Hydrocarbon/antagonists & inhibitors , Receptors, Aryl Hydrocarbon/genetics , Receptors, Aryl Hydrocarbon/metabolism , Recombinant Proteins/metabolism , Transforming Growth Factor beta1/genetics
8.
Neoplasia ; 13(6): 526-36, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21677876

ABSTRACT

Although the induction of senescence in cancer cells is a potent mechanism of tumor suppression, senescent cells remain metabolically active and may secrete a broad spectrum of factors that promote tumorigenicity in neighboring malignant cells. Here we show that androgen deprivation therapy (ADT), a widely used treatment for advanced prostate cancer, induces a senescence-associated secretory phenotype in prostate cancer epithelial cells, indicated by increases in senescence-associated ß-galactosidase activity, heterochromatin protein 1ß foci, and expression of cathepsin B and insulin-like growth factor binding protein 3. Interestingly, ADT also induced high levels of vimentin expression in prostate cancer cell lines in vitro and in human prostate tumors in vivo. The induction of the senescence-associated secretory phenotype by androgen depletion was mediated, at least in part, by down-regulation of S-phase kinase-associated protein 2, whereas the neuroendocrine differentiation of prostate cancer cells was under separate control. These data demonstrate a previously unrecognized link between inhibition of androgen receptor signaling, down-regulation of S-phase kinase-associated protein 2, and the appearance of secretory, tumor-promoting senescent cells in prostate tumors. We propose that ADT may contribute to the development of androgen-independent prostate cancer through modulation of the tissue microenvironment by senescent cells.


Subject(s)
Androgen Antagonists/pharmacology , Cellular Senescence/drug effects , Down-Regulation/drug effects , S-Phase Kinase-Associated Proteins/metabolism , Blotting, Western , Cathepsin B/metabolism , Cell Line, Tumor , Flow Cytometry , Humans , Insulin-Like Growth Factor Binding Protein 3/metabolism , Male , Microscopy, Confocal , PTEN Phosphohydrolase/metabolism , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , RNA Interference , Receptors, Androgen/metabolism , S-Phase Kinase-Associated Proteins/genetics , Signal Transduction/drug effects , Vimentin/metabolism , beta-Galactosidase/metabolism
9.
Cell Signal ; 22(11): 1734-44, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20603212

ABSTRACT

Chronic inflammation plays an important role in the initiation and progression of various human diseases including benign prostatic hyperplasia or prostate cancer. Here we show that the proinflammatory cytokine interleukin-6 (IL-6) has prosurvival effects and chronically activates the Jak2/STAT3 signalling pathway in a model of benign prostatic hyperplasia (BPH-1). We demonstrate that the antiinflammatory cytokine transforming growth factor-beta1 (TGF-beta1), which also permanently activates its canonical signalling pathway through SMAD proteins in BPH-1 cells, modifies the effects of IL-6 on cell proliferation. Importantly, TGF-beta1 inhibits IL-6 signal transduction by decreasing the phosphorylation levels of STAT3. This effect is associated with decreased expression of Jak2 at both mRNA and protein levels. Moreover, we showed that TGF-beta1 inhibits IL-6-induced expression of the cancer-associated gene MUC1. These observations demonstrated a novel interaction between TGF-beta1 and IL-6 signalling and suggested another mechanism of how defects in TGF-beta signalling, frequently associated with prostate pathologies, can contribute to the disruption of tissue homeostasis.


Subject(s)
Epithelial Cells/metabolism , Interleukin-6/antagonists & inhibitors , Janus Kinase 2/metabolism , Prostate/metabolism , Prostatic Hyperplasia/metabolism , STAT3 Transcription Factor/metabolism , Transforming Growth Factor beta1/pharmacology , Cell Line , Cell Proliferation , Humans , Interleukin-6/pharmacology , Janus Kinase 2/genetics , Male , Mucin-1/metabolism , Phosphorylation , Prostate/cytology , Prostate/enzymology , Prostatic Hyperplasia/enzymology , RNA Interference , RNA, Small Interfering/metabolism , Signal Transduction , Smad Proteins/metabolism
10.
Cancer Genet Cytogenet ; 197(2): 107-16, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20193843

ABSTRACT

Stable cell lines obtained by spontaneous immortalization might represent early stages of malignant transformation and be useful experimental models for studies of mechanisms of cancer development. The FHC (fetal human cells) cell line has been established from normal fetal colonic mucosa. Detailed characterization of this cell line and mechanism of spontaneously acquired immortality have not been described yet. Therefore, we characterized the FHC cell line in terms of its tumorigenicity, cytogenetics, and TP53 gene mutation analysis. FHC cells displayed capability for anchorage-independent growth in semisolid media in vitro and formed solid tumors after transplantation into SCID (severe combined immunodeficiency) mice. This tumorigenic phenotype was associated with hypotriploidy and chromosome number ranging from 66 to 69. Results of comparative genetic hybridization arrays showed that most chromosomes included regions of copy number gains or losses. Region 8q23 approximately 8q24.3 (containing, e.g., MYC proto-oncogene) was present in more than 20 copies per nucleus. Moreover, we identified mutation of TP53 gene in codon 273; triplet CGT coding Arg was changed to CAG coding His. Expression of Pro codon 72 polymorphic variant of p53 was also detected. Mutation of TP53 gene was associated with abolished induction of p21(Waf1/Cip1) and MDM-2 proteins and resistance to apoptosis after genotoxic treatment. Because of their origin from normal fetal colon and their relative resistance to the induction of apoptosis, FHC cells can be considered a valuable experimental model for various studies.


Subject(s)
Colon/physiology , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Genes, p53 , Animals , Apoptosis/physiology , Carcinoembryonic Antigen/metabolism , Cell Adhesion/physiology , Cell Growth Processes/physiology , Cell Line, Transformed , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Colon/cytology , Colon/metabolism , Comparative Genomic Hybridization , Cytogenetic Analysis/methods , DNA Damage , DNA Mutational Analysis/methods , Female , Fetus/cytology , HCT116 Cells , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Keratins/metabolism , Mice , Mice, SCID , Neoplasm Transplantation , Phenotype , Proto-Oncogene Mas , Signal Transduction
11.
Biochem Pharmacol ; 78(6): 561-72, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19433066

ABSTRACT

Antitumorigenic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are well established in several types of cancer disease. However, the mechanisms driving these processes are not understood in all details. In our study, we observed significant differences in sensitivity of cancer epithelial cell lines to COX-independent antiproliferative effects of NSAIDs. The prostate cancer cell line LNCaP, lacking both critical enzymes in the negative control of PKB/Akt activation, PTEN and SHIP2, was the most sensitive to these effects, as assessed by analysing the cell cycle profile and expression of cell cycle regulating proteins. We found that p53 protein and its signalling pathway is not involved in early antiproliferative action of the selected NSAID-indomethacin. RNAi provided evidence for the involvement of p21(Cip1/Waf1), but not GDF-15, in antiproliferative effects of indomethacin in LNCaP cells. Interestingly, we also found that indomethacin activated PKB/Akt and induced nuclear localisation of p21(Cip1/Waf1) and Akt2 isoform. Our results are in agreement with other studies and suggest that maintaining of the p21(Cip1/Waf1) level and its intracellular localisation might be influenced by Akt2. Knock-down of SHIP2 by RNAi in PTEN negative prostate and colon cancer cell lines resulted in higher sensitivity to antiproliferative effects of indomethacin. Our data suggest novel mechanisms of NSAIDs antiproliferative action in cancer epithelial cells, which depends on the status of negative regulation of the PKB/Akt pathway and the isoform-specific action of Akt2. Thus, unexpectedly, multiple defects in negative regulation of the PKB/Akt pathway may contribute to increased sensitivity to chemopreventive effects of these widely used drugs.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cell Cycle/drug effects , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Epithelial Cells/drug effects , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-akt/metabolism , Tumor Suppressor Protein p53/metabolism , Antineoplastic Agents/pharmacology , Cell Cycle/physiology , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Enzyme Induction , Epithelial Cells/pathology , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression/drug effects , Growth Differentiation Factor 15/biosynthesis , Humans , Indomethacin/pharmacology , Male , Phosphatidylinositol 3-Kinases , RNA Interference , Signal Transduction/drug effects , Signal Transduction/physiology , Tumor Suppressor Protein p53/genetics
SELECTION OF CITATIONS
SEARCH DETAIL